Zoltan Nagy - Lotus Bio President CEO, Director
| LBTD Stock | USD 0.01 0.00 0.00% |
CEO
Mr. Zoltan Nagy is President, Chief Executive Officer, Director of the Company. He was President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Secretary, Director of the Company. Since August 30, 2007, Mr. Nagy was president, chief executive officer, treasurer, secretary and a director of Raptor Technology Group, Inc., a Nevada corporation whose common stock is traded on the Bulletin Board under the symbol RAPT. Raptor Technology Group, Inc. is engaged in the business of fabrication of equipment. Since 2002, Mr. Nagy was active in the filmed entertainment industry as an actor, production assistant, camera operator and director on several television shows, commercials and motion pictures. Mr. Nagy received a diploma in film direction from Los Angeles City College in 1993. since 2019.
| Age | 57 |
| Tenure | 5 years |
| Phone | 480-275-2294 |
| Web | www.lotusbiotechnologies.com |
Lotus Bio Management Efficiency
The company has return on total asset (ROA) of (4.213) % which means that it has lost $4.213 on every $100 spent on assets. This is way below average. Lotus Bio's management efficiency ratios could be used to measure how well Lotus Bio manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | CEO Age | ||
| Mary Erdoes | JPMorgan Chase Co | 57 | |
| Marc Lore | Walmart | 47 | |
| Charles Robbins | Cisco Systems | 58 | |
| Douglas Petno | JPMorgan Chase Co | 55 | |
| Daniel Pinto | JPMorgan Chase Co | 61 | |
| Judith McKenna | Walmart | 57 | |
| Jennifer Piepszak | JPMorgan Chase Co | 53 | |
| John Furner | Walmart | 49 | |
| Marianne Lake | JPMorgan Chase Co | 54 | |
| Kathryn McLay | Walmart | 50 | |
| Jon Isaac | Live Ventures | 41 | |
| Thomas Taylor | Floor Decor Holdings | 58 | |
| C McMillon | Walmart | 53 | |
| Alan Schnitzer | The Travelers Companies | 58 | |
Management Performance
| Return On Asset | -4.21 |
Lotus Bio Technology Leadership Team
Elected by the shareholders, the Lotus Bio's board of directors comprises two types of representatives: Lotus Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lotus. The board's role is to monitor Lotus Bio's management team and ensure that shareholders' interests are well served. Lotus Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lotus Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zoltan Nagy, President CEO, Director | ||
| Hoyt Christopher, Chief Officer |
Lotus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lotus Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -4.21 | |||
| Current Valuation | 31.31 M | |||
| Shares Outstanding | 782.77 M | |||
| Shares Owned By Insiders | 60.40 % | |||
| Price To Earning | (1.71) X | |||
| Net Income | (19.55 K) | |||
| Cash And Equivalents | 1 | |||
| Total Debt | 16.68 K | |||
| Cash Flow From Operations | (17.75 K) | |||
| Beta | -1.44 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Lotus Pink Sheet
Lotus Bio financial ratios help investors to determine whether Lotus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lotus with respect to the benefits of owning Lotus Bio security.